“Ipamorelin helps people lose body fat.”
No study in people has tested whether ipamorelin helps with fat loss.
Ipamorelin is an untested fat-loss idea with real safety warnings. If you want medical help with weight loss, there are approved treatments with real trial results.
Skip ipamorelin, and if you want help with weight loss, ask your doctor about approved options.
Safety note: FDA has flagged a published report of serious side effects, including death, when ipamorelin was given by IV. Injected peptides like ipamorelin may also trigger immune reactions. Ipamorelin is not an approved medicine, and it is banned in sport at all times.
Talk to a healthcare professional if: you are thinking about injecting ipamorelin or another growth hormone peptide for weight loss.
We found no study in people that measured body fat with ipamorelin. The main human trial tested it for bowel recovery after surgery, so the fat-loss question has not been tested.
No study in people has tested whether ipamorelin helps with fat loss. The main human trial tested it for bowel recovery after surgery, not fat loss, and it did not show a clear benefit.
In that 2014 trial, 117 people having bowel surgery got ipamorelin or a placebo by IV twice a day for up to a week. Time to the first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, a difference that could have been chance, and the other measures did not differ. Ipamorelin raises growth hormone, and a 2020 review of growth hormone boosters said clinical data on their effects on body composition are largely lacking. Results from other peptide or weight-loss drugs do not carry over to ipamorelin.
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29(12):1527-1534. DOI: 10.1007/s00384-014-2030-8. PMID: 25331030
- Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159. DOI: 10.21037/tau.2019.11.30. PMID: 32257855. PMCID: PMC7108996
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of April 22, 2026
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In effect January 1, 2026